Abstract:The adoptive transfer of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 has shown remarkable activity for patients with B cell malignancies. Using a second- generation CAR signaling through 4-1BB/CD3ζ, (CTL019), over 90% of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) will achieve complete remission (Maude, S.L. et. al. New England Journal of Medicine, 2014). Similar therapy can induce long-term remissions for R/R chronic lymphocytic leukemia (CLL), but only in a subset of patients (Porter, D.L. et. al. Science Transl. Medicine, 2015). The ability to identify individuals most likely to respond will have a dramatic impact on patient selection and provide critical information that may allow immune modification to enhance responses using this approach. We here present updated analyses and functional validation of our previously reported biomarker profiles of CTL019 cells in CLL (Fraietta, J.A. et. al., Blood, 2016). Retrospective samples of clinically manufactured CAR T cells from forty-one patients with advanced, heavily pre-treated and high-risk CLL were evaluated for functional determinants of potency. Transcriptomic analysis of CTL019 cells from subjects who had complete responses (CR) to this therapy revealed enrichment in early memory T cells and IL-6/STAT3 gene signatures, while T cells from non-responding (NR) patients were enriched in genes belonging to known pathways of terminal differentiation, exhaustion, apoptosis and glycolysis. Accordingly, CAR-stimulated T cells from NR relative to CR patents demonstrated an increased uptake of a glucose analog; inhibition of glycolysis using 2-deoxy-D-glucose resulted in the generation of early memory CAR T cells in culture. Furthermore, CTL019 cells that were highly functional in CLL patients had increased levels of phosphorylated STAT3 (pSTAT3) upon activation compared to CAR T cells from NR patients with poor anti-tumor activity. These data were concordant with the highly significant direct correlation between serum IL-6 and the degree of CTL019 proliferative capacity in patients. Increasing pSTAT3 activity by addition of exogenous IL-6 to culture media elevated the absolute numbers of CAR T cells following repeated stimulation with CD19-expressing tumor targets, while pSTAT3 inhibition diminished CTL019 cell growth. Single-cell proteomic analysis of CAR-stimulated CTL019 cells from CLL patients revealed marked heterogeneity in cytokine secretions and enhanced polyfunctional strength in CAR T cells from responding over non-responding patients. There were multiple contributors to CTL019 cell polyfunctional strength, including granzyme B, MIP-1α, IFNg, TNFα, IL-5, IL-8, MIP-1β and perforin. We next performed deep immunophenotyping on the above pre-infusion CAR T cells and, through unbiased computational analysis of the flow cytometry data, defined a single subset (CD8+CD27-PD1-) that segregated CRs from NRs. Importantly, we noted a highly significant association between the likelihood of having a response to CTL019 therapy and the infusion of CTL019 products containing a high dose of CD8+PD1-CD27+ CAR T cells. To confirm that this cell population drives the response to CTL019 therapy, we depleted it from CR patient CTL019 cells and observed loss of tumor control and decreased survival in leukemia-bearing NOD scid gamma (NSG) mice compared to animals treated with subject-matched unmanipulated cellular products. These findings, coupled with our previous results, reveal a functionally relevant T lymphocyte population that can serve as a novel predictive biomarker and a framework for future mechanistic dissection to enhance the efficacy of CAR T cell therapies. Disclosures Fraietta: Novartis: Patents & Royalties: patents, Research Funding. Lacey: Novartis: Research Funding; Genentech: Honoraria. Orlando: Novartis: Employment. Pruteanu: Novartis Pharmaceuticals Corporation: Employment. OConnor: Novartis: Research Funding. Chen: Novartis: Research Funding. Davis: Novartis: Research Funding. Young: Novartis: Research Funding. Levine: Brammer Bio: Consultancy; Tmunity Therapeutics: Equity Ownership, Research Funding; GE Healthcare: Consultancy; Novartis Pharmaceuticals Corporation: Patents & Royalties, Research Funding. Siegel: Novartis: Research Funding. Zhou: IsoPlexis: Employment, Equity Ownership. Paczkowski: IsoPlexis: Employment, Equity Ownership. Mackay: IsoPlexis: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Speakers Bureau. Brogdon: Novartis: Employment. Bitter: Novartis: Employment. Porter: Incyte: Honoraria; Novartis: Honoraria, Patents & Royalties, Research Funding; Servier: Honoraria, Other: Travel reimbursement; Genentech/Roche: Employment, Other: Family member employment, stock ownship - family member; Immunovative Therapies: Other: Member DSMB. June: Tmunity Therapeutics: Equity Ownership, Research Funding; WIRB/Copernicus Group: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celldex: Honoraria, Membership on an entity's Board of Directors or advisory committees; Immune Design: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Novartis: Patents & Royalties, Research Funding. Melenhorst: Novartis: Research Funding.

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen-induced exhaustion

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics

IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Abstract 891: CD70-targeting CAR-T and CAR-NK cells demonstrate potent activity against NSCLC drug-tolerant persister cells

An NK-like CAR T cell transition in CAR T cell dysfunction

CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-? for cancer immunotherapy

Abstract 5512: CBLB, CISH and CD70 Multiplexed Gene Knockout with CRISPR/Cas9 Enhances Cytotoxicity of CD70-CAR NK Cells and Provides Greater Resistance to TGF-β for Cancer Immunotherapy

Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies

Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy

Abstract PO1-26-05: Animal Study Compares CAR T cell Exhaustion & Ability to Kill Low Antigen expressing breast cancer cells among three CAR constructs including one with 1XX mutations

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

CD70 CAR NK Cells in the Treatment of Multiple Myeloma

Abstract LB070: In vitro modeling of antigen-driven exhaustion in human CAR T cells

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors